· Pharma · Pharma Desk
Novo Nordisk's oral semaglutide enters a field about to be contested by Lilly's orforglipron — a modality shift with implications for adherence, GI tolerability, and pricing.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.